CagriSema Significantly Outperforms Semaglutide for Greater Weight Loss in Obesity

The global prevalence of obesity continues to rise, posing a significant public health challenge and increasing the risk of numerous comorbidities like type 2 diabetes and cardiovascular disease. While GLP-1 receptor agonists like semaglutide have revolutionized weight management, there's a continuous search for even more effective pharmacological interventions. This systematic review and meta-analysis aimed to comprehensively compare the efficacy and safety of the novel combination therapy, CagriSema, against semaglutide monotherapy or placebo for obesity treatment.

The meta-analysis revealed that CagriSema demonstrated significantly superior body weight reduction compared to both semaglutide monotherapy and placebo. Participants treated with CagriSema achieved an average 15.6% reduction in body weight from baseline, which was significantly greater than the 9.9% reduction observed with semaglutide monotherapy (p<0.001). This translates to an additional 5.7% mean body weight loss with CagriSema over semaglutide alone. Furthermore, CagriSema led to a remarkable 18.1% weight reduction compared to a mere 2.8% with placebo (p<0.001). The proportion of participants achieving at least 15% weight loss was 68% with CagriSema, compared to 43% with semaglutide (p<0.001). While gastrointestinal adverse events (e.g., nausea, vomiting) were more frequent with CagriSema (e.g., 78% vs 65% for semaglutide), they were generally mild to moderate and transient.